Michael Gillett

All publications

Journal articles

• Thomas C, Sadler S, Breeze P, Squires H, Gillett M & Brennan A (2017) Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. BMJ Open, 7. View this article in WRRO
• Dunkley A, Tyrer F, Spong R, Gray L, Gillett MJ, Doherty Y, Martin-Stacey L, Patel N, Yates T, Bhaumik S , Chalk T et al (2017) Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. Programme Grants for Applied Research, 5(11). View this article in WRRO
• Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W , Masters S et al (2016) The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 20(90). View this article in WRRO
• Yates T, Griffin S, Bodicoat DH, Brierly G, Dallosso H, Davies MJ, Eborall H, Edwardson C, Gillett M, Gray L , Hardeman W et al (2015) PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. Trials, 16(1).
• Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, Gillett M, Elliott J & Heller S (2014) Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model.. Diabet Med, 31(4), 477-486.
• (2013) Corrigendum. Diabetic Medicine, 30(5), 632-632.
• Johnson M, Jones R, Freeman C, Woods HB, Gillett M, Goyder E & Payne N (2013) Can diabetes prevention programmes be translated effectively into real-world settings and still deliver improved outcomes? A synthesis of evidence.. Diabet Med, 30(1), 3-15. View this article in WRRO
• Gillett M, Royle P, Snaith A, Scotland G, Poobalan A, Imamura M, Black C, Boroujerdi M, Jick S, Wyness L , McNamee P et al (2012) Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation.. Health Technol Assess, 16(33), 1-iv.
• Gillett M, Dixon S, Dallosso HM, Brennan A, Carey ME, Campbell MJ, Heller S, Khunti K, Skinner TC & Davies MJ (2010) Self management of diabetes Authors' reply. BRIT MED J, 341.
• Goyder E, Simmons R & Gillett M (2010) Who can prevent diabetes? Current issues in the prevention of type 2 diabetes. J R Coll Physicians Edinb, 40(Suppl 17), 5-11.
• Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, Heller S, Khunti K, Skinner TC & Davies MJ (2010) Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.. BMJ, 341, c4093.
• Palmer AJ, Roze S, Valentine WJ, McEwan P, Gillett M, Holmes M, Clarke P, Stevens R, Gray AM, Coleman R , Sorensen S et al (2007) Computer modeling of diabetes and its complications - A report on the Fourth Mount Hood Challenge Meeting. DIABETES CARE, 30(6), 1638-1646.
• Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R & John A (2007) Screening for type 2 diabetes: literature review and economic modelling. HEALTH TECHNOL ASSES, 11(17), 1-+.
• Whitfield MD, Gillett M, Holmes M & Ogden E (2006) Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.. Public Health, 120(12), 1140-1148.
• Ray K, Bolton J, Veitch A, Sheridan P, Gillett M, Al Rifai A, ManivArmane R, Brennan A, Payne P & Baig W (2004) Risk of death, myocardial infarction and patterns of care delivered in non-ST elevation ACS patients with intermediate elevations in cardiac troponin T: a UK District General Hospital experience. British Journal of Cardiology, 12(2).
• Gillett M, Brennan A, Watson P, Khunti K, Davies M, Mostafa S & Gray LJ () The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment, 19(33), 1-80.

Conference proceedings papers

• Luqmani RA, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W , Masters S et al (2016) INTERRATER AND INTRARATER ANALYSIS OF ULTRASOUND AND HISTOLOGICAL FINDINGS IN PATIENTS WITH SUSPECTED GIANT CELL ARTERITIS. RHEUMATOLOGY, Vol. 55 (pp 171-171)
• Luqmani RA, Lee E, Singh S, Gillett M, Schmidt W, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W , Masters S et al (2016) ULTRASOUND COMPARED WITH BIOPSY IN THE DIAGNOSIS OF SUSPECTED GIANT CELL ARTERITIS. RHEUMATOLOGY, Vol. 55 (pp 37-37)
• Brennan A & Gillett M (2010) MODELLING COST EFFECTIVENESS OF BEHAVIOUR MODIFICATION PROGRAMMES AND EFFECTS ON MEDICATION: CASE STUDY OF EDUCATION PROGRAMMES IN DIABETES. VALUE HEALTH, Vol. 13(3) (pp A59-A59)
• Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, Heller S, Khunti K & Davies MJ (2009) Cost effectiveness of the DESMOND structured education programme for patients newly diagnosed with type 2 diabetes. DIABETOLOGIA, Vol. 52 (pp S12-S12)
• Brennan A, Gillett M & Duenas A (2008) ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL. VALUE HEALTH, Vol. 11(6) (pp A501-A501)

Posters

• Brennan A & Gillett M Modelling cost effectiveness of behaviour modification programmes and effects on medication: case study of education programmes in diabetes.